Our India footprint
We are headquartered in Mumbai with 7 regional and sales hubs across the country. The company has made substantial investments in two large manufacturing facilities – Nashik, in the state of Maharashtra and an upcoming facility in Vemgal, in the state of Karnataka
Inaugurated in 1983, Nashik factory is situated on 47 acres of land in Ambad industrial belt. The facility manufactures tablets, creams and ointments and has a committed workforce of over 800 people. The facility is committed to conserving natural resources and ensuring operational safety in all its processes. The site ensures its sustainability through energy conservation and environment friendly processes to manufacture high quality affordable products. It strives to automate operations by implementing indigenously developed technology, thus improving productivity and efficiency. The facility has received various accolades in the areas of operational safety, environment protection, energy and water conservation and ergonomics.
The new Eltroxin manufacturing facility in our current Nashik site became operational recently.
GSK has invested more than ₹1000 crores in a new state-of-the-art pharmaceutical manufacturing facility in Vemgal, in the state of Karnataka. The facility will initially supply a range of solid dose form products. In its full capacity, the facility will produce more than 8 billion tablets and 1 billion capsules per year.
Global R&D support groups in Bengaluru, Karnataka
- Global Regulatory Platforms and Delivery (GRPD): GRPD is a regulatory affairs function that brings together critical capabilities for GSK, such as regulatory dossier production, regulatory life cycle management, global labeling and regulatory information management.
- Clinical Development Operations Centre (CDOC) : CDOC works on data handling, study set-up, scientific and public disclosure, biometrics, quality risk management and clinical project management.
- Biostatistics India : Biostatistics team provides statistical and SAS programming support to clinical and epidemiology studies within GSK’s research and development department.
- Safety Sciences India (SSI) : The SSI team is an enterprise platform that is involved with safety surveillance activities for all GSK generic products and some of the consumer health products. The team performs global literature search to screen articles for potential ICSRs/Articles of interest, involved in reconciliation of safety data exchange agreements and systems support.